Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aptiv Solutions Growing: Opens New Office in North Carolina

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
New office is located at 4505 Emperor Boulevard in the Imperial Center.

Aptiv Solutions has announced the opening of a new office in Durham, North Carolina.

The new office is located at 4505 Emperor Boulevard in the Imperial Center, an elite business park convenient to Raleigh, Durham, Chapel Hill, Cary and Research Triangle Park.

Aptiv Solutions and its subsidiary Trio Clinical Resourcing previously resided in separate offices in Raleigh and Morrisville.

The decision to combine the offices arose from growth of staff and the desire to co-locate the North Carolina based teams.

The new office includes team members from the clinical, data management and biostatistics, regulatory, translational sciences, medical consulting, pharmacovigilance, quality assurance, proposal development, information technology, finance, business development and human resources teams for Aptiv Solutions and the Trio Clinical Resourcing team.

“We are delighted to have our Aptiv Solutions and Trio Clinical Resourcing teams all under one roof in the new Durham, North Carolina office,” commented Pat Donnelly, Chairman and CEO of Aptiv Solutions.

Donnelly continued, “We continue to experience rapid growth as we expand to meet the expansion in our client base. Our new office not only accommodates our current staff levels, but allows for the anticipated future growth of our North Carolina operations”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!